- Conditions
- Psoriasis
- Interventions
- Ixekizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 31
- States / cities
- Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–90
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plaque-type Psoriasis
- Interventions
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
- Conditions
- Plaque-type Psoriasis
- Interventions
- CD 2027
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Hot Springs, Arizona • Austin, Texas • Bryan, Texas
- Conditions
- Psoriatic Plaque
- Interventions
- KBL697
- Drug
- Lead sponsor
- KoBioLabs
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 3 more
- Conditions
- Psoriasis
- Interventions
- Calcipotriene 0.005% Foam
- Drug
- Lead sponsor
- Mayne Pharma International Pty Ltd
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
- Conditions
- Psoriasis
- Interventions
- Secukinumab
- Drug
- Lead sponsor
- Saakshi Khattri
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
- Drug
- Lead sponsor
- QuatRx Pharmaceuticals Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 12
- States / cities
- Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more
- Conditions
- Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
- Interventions
- IRX4204, Placebo
- Drug · Other
- Lead sponsor
- Io Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Webster, Texas
- Conditions
- Psoriasis
- Interventions
- Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Drug
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
- Conditions
- Psoriasis
- Interventions
- Apremilast, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
- Conditions
- Parapsoriasis, Healthy Volunteers
- Interventions
- CC-90005, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Psoriasis
- Interventions
- CP-690,550, Placebo/CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
- Conditions
- Psoriasis
- Interventions
- Calcipotriene Foam, Vehicle Foam
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 22 more
- Conditions
- Plaque Type Psoriasis
- Interventions
- GP2017 Adalimumab, Humira ® Adalimumab
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- Secukinumab (AIN457), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
- Conditions
- Psoriasis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
- Conditions
- Chronic Plaque Psoriasis, Psoriasis
- Interventions
- M923, Humira
- Biological
- Lead sponsor
- Momenta Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • Encino, California • La Mesa, California + 20 more
- Conditions
- Psoriasis
- Interventions
- CD 2027, Calcitriol Vehicle
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Fridley, Minnesota • Nashville, Tennessee